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Abstract
Background: A recent study found lower self-reported prevalence of tobacco smoking in a peri-urban area of Lima,
Peru than previously reported in urban samples. These regions encompass substantial proportions of Peru’s
population – ones at greater risk of disease due to reduced healthcare access – but have been less often studied.
We validate low smoking prevalence with urine cotinine and characterize chronic disease and lung function
outcomes between non-, occasional, and daily smokers.
Methods: Data are from the CRONICAS Cohort Study, a population-based longitudinal study in four low-resource
Peruvian settings, which began in 2010. Of a baseline cohort of 2978 adults, we prospectively followed 2583 (87%)
to determine prevalence of chronic illness.
Results: In a baseline sub-sample of 382 participants, median adjusted cotinine was 0.0 mcg/mg (IQR 0–0) for both
self-reported non-smokers and occasional smokers compared to 172.3 mcg/mg (IQR 0–709.2) for daily smokers.
Creatinine-adjusted cotinine validated daily smoking prevalence of 4.7% at a cutoff of 100 mcg/mg. Kappa statistic
for daily smoking and creatinine- adjusted cotinine ≥100 mcg/mg was 0.65 (95% CI 0.47, 0.83), indicating substantial
agreement. At baseline, we found 3.3% daily and 8.9% occasional smoking by self-report for the full cohort. Follow-
up indicated little difference in chronic disease prevalence between groups. Daily smokers trended toward having a
greater decline in FVC (−1%; 95% CI -2.9, 0.8) and FEV1 (−1.3%; 95% CI -3.2, 0.6) over 40 months when compared to
non-smokers, whereas the decline in lung function for occasional smokers was similar compared to non-smokers
(−0.2% FVC; 95% CI -1.5, 1.0) and (0% FEV1; 95% CI -1.3, 1.3).
Conclusions: Our data places Peru within a previously-described pattern of smoking found in much of Latin
America, favoring occasional over daily smoking and low cigarette consumption. We determine that there are not
significant differences between smoking groups concerning chronic disease outcomes. We favor distinguishing
between daily and occasional smokers in order to accurately characterize these low-use populations.
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Background
While tobacco smoking has declined dramatically in
high-income countries, data suggests that it may be
increasing in low- and middle-income countries
(LMICs). This rise in smoking stands to accelerate
countries’ epidemiologic transitions, contributing to
increasing rates of chronic disease morbidity and
mortality [1, 2]. In these countries, accurate tobacco
use data is essential for public health practitioners
designing and implementing interventions to curb
smoking and prevent chronic disease.
This work focuses on Peru as a case study. Peru is
an LMIC showing early signs of increasing chronic
disease, but an uncertain smoking landscape. Earlier
studies that have attempted to estimate the prevalence
of smoking in Peru have largely focused on urban
areas, overlooking peri-urban shantytowns. The
CARMELA study reported that the prevalence of
current tobacco use – roughly, anyone who reported
current daily or occasional inhaled tobacco use –
among those aged 25–64 years in urban Lima, Peru
was 26.6% in 2005 [3]. The same year, the Center for
Information and Education for the Prevention of Drug
Abuse in Peru reported a 27.7% prevalence of all
smoking and a 7.7% prevalence of daily smoking
among those aged 12–64 years, also in urban Lima
[4]. Meanwhile, our group estimated in a 2012 study
that smoking prevalence may be substantially lower in
peri-urban Lima, with a prevalence estimate of 16%
for cigarette smoking among adults ≥40 years old [5].
Importantly, only 2% of the sample were daily smokers
with the balance reporting occasional smoking [5]. This
finding, if true, has important public health implications
for Peru. Given the increasing proportion of Peruvians
residing in peri-urban zones, high-quality surveillance
must be directed to these areas to derive estimates of
chronic disease prevalence and risk.
Our first objective was to describe the tobacco-
using population of peri-urban Peru by validating our
low self-reported finding smoking prevalence with
urine cotinine. Cotinine, the primary metabolite of
nicotine, is a reliable [6] and valid [7, 8] biomarker
that has been long used as a surrogate for tobacco
smoke exposure in the previous 48 h [9–22]. We
compared the prevalence of smoking by self-report
with that based on a laboratory analysis of urine
cotinine in a population-based sample of 382 adults
from low-income peri-urban Lima and semi-urban
Tumbes, Peru. Our second objective was to
characterize the chronic disease burden in Peru, espe-
cially related to smoking status. To accomplish this,
we compared chronic disease diagnoses, respiratory
symptoms, biomarkers, and lung function scores over
a 40-month follow up period between self-reported
daily, occasional, and non-smokers over four separate
field sites. For this analysis, we utilized our full co-
hort of 2978 adult participants.
Methods
Study design and setting
We utilized self-report and biomarker data collected
at baseline in a random subsample of participants in
the CRONICAS cohort, a prospective longitudinal
study on cardiovascular disease, hypertension,
diabetes, and lung function for which data collection
began in September 2010 [23]. Recruitment sites
were chosen to represent a cross-section of low-
income populations in Peru. These areas represent a
large percentage of Peru’s population and have ac-
cess to fewer health resources; however, they are less
often studied as they are not as accessible as urban
populations [5]. Pampas de San Juan de Miraflores is
a physically diverse, peri-urban community 25 km
south of Lima’s city center, and home to a large
population of Andean immigrants which, studies
have shown, suffer worsening cardiovascular risk
profiles with urbanization similar to lifelong urban
residents [24]. It represents a somewhat urbanized
location at sea level with high ambient air pollution
and low use of biomass fuels. Tumbes, on Peru’s
northern coast, is a mix of rural areas and growing
urban sections. It is much less densely populated
than the Lima site and represents a semi-urban
location at sea level with low ambient air pollution
and high biomass fuel use. Puno, in southeastern
Peru, is home to two recruitment sites of 500 partic-
ipants each, one rural and one urban. They are both
at high altitude and feature low ambient air pollu-
tion; however, biomass fuel use, while rare in the
urban site, is prevalent in the rural site.
Participants, recruitment, and ethics
Individuals were randomly selected from census data
to form simple age- and sex-stratified cohorts of
around 1000 participants per site. Study personnel
visited the households of selected individuals to invite
them to participate, ascertain oral consent (due to
high rates of illiteracy), and perform baseline data
collection. A random sub-sample of participants from
Lima and Tumbes was invited to participate in ancil-
lary studies (Puno was not included due to financial
constraints). Inclusion criteria included age ≥ 35 years
and permanent residency of the area. Exclusion
criteria included pregnancy, physical or mental
disability (sufficient to impede implementation of the
study protocol), and active pulmonary tuberculosis.
The study protocol was reviewed and approved by
the Institutional Review Boards of Johns Hopkins
Morgan et al. Tobacco Induced Diseases  (2017) 15:32 Page 2 of 10
University in Baltimore, USA, and A.B. PRISMA and
Universidad Peruana Cayetano Heredia in Lima, Peru.
Data collection
Data collection is described in detail elsewhere [23].
Briefly, baseline data collected during the recruitment
visit included demographic, socioeconomic, and
lifestyle risk factors (including smoking status); bio-
mass exposure; and cardiovascular and respiratory
symptoms, and was modified from WHO’s STEP
questionnaire for non-communicable disease and the
Global Adult Tobacco Survey (GATS) [25, 26]. Dur-
ing the initial visit, appointments were made for a clin-
ical evaluation. At the clinic, lung function was ascertained
with a portable spirometer (Easy-On-PC, ndd, Zurich,
Switzerland) both pre- and post-administration of salbuta-
mol. Blood and urine were collected by a trained techni-
cian. The date of collection of biological samples ranged
from 22 days before survey to 228 days afterward. Whole
blood and plasma were collected in ethylenediaminetetra-
acetic acid (EDTA) containing tubes and sodium fluoride/
EDTA tubes, respectively, while urine was collected in
15 mL containers. Samples were stored at 4–8 °C for two
weeks before being moved to a storage facility where the
urine was separated into four 1.5 mL vials. Samples were
then kept at −20 °C until laboratory analysis. Our biological
samples were all analyzed in a single laboratory. Assay qual-
ity was validated against external standards and internal du-
plicate assays and were monitored by BioRad (http://
www.bio-rad.com). Methods for the measurement of
plasma glucose, serum insulin, hemoglobin A1c, total chol-
esterol, and HDL cholesterol are outlined in the parent
sub-study protocol [27]. Urine creatinine was measured via
modified kinetic Jaffé method. Urine cotinine was analyzed
via gas chromatography-mass spectrometry [28]. The limit
for detection was 0.16 ng/mL. We present urine cotinine
both unadjusted and standardized by level of urine creatin-
ine (cotinine/creatinine ratio).
Definitions
Self-reported smoking was defined by the answer to
the question, “Do you currently smoke cigarettes
daily, occasionally, or not at all?” Current smoking was de-
fined as a response of “Occasionally” (<1 cigarette/day) or
“Daily” (1+ cigarettes/day) while daily (active) smoking was
defined as only those who responded “Daily.” Based on pre-
vious research, adjusted urine cotinine was categorized into
“none” (<10 mcg/mg), “low” (10–100 mcg/mg), and “high”
(≥100 mcg/mg), which were used as references for our clas-
sifications of non-smoking, occasional/passive smoking,
and daily (active) smoking, respectively [20, 29–33].
Fasting glucose, insulin, HbA1c, HDL, LDL, total chol-
esterol, and triglycerides were taken from blood samples.
Diabetes mellitus was defined as self-reported physician
diagnosis, use of anti-diabetic medications, or fasting
plasma glucose ≥126 mg/dL [34]. Hypertension was
defined as self-reported physician diagnosis, systolic
blood pressure (SBP) ≥140 mmHg, diastolic blood pres-
sure (DBP) ≥90 mmHg, or receipt of anti-hypertensive
therapy [35].
Insulin resistance was assessed using the homeostasis
model assessment (HOMA-IR) by Matthews et al. [36].
The Framingham risk score (FRS) was calculated from
the National Cholesterol Education Program Adult
Treatment Panel III algorithm, which is based on cardio-
vascular risk factors, including age, sex, total cholesterol,
HDL-cholesterol, systolic BP and smoking status [37].
Socioeconomic status was assessed using a wealth index
based upon occupation, assets, and household income
and facilities [38]. Body mass index (BMI) was calculated
as weight (kg) divided by height (m) squared.
Biostatistical methods
To validate the prevalence of active smokers in peri-
urban areas, prevalence estimates are reported as means
with 95% confidence intervals. Differences between
recruitment sites were examined using Chi-square tests
for categorical variables and Wilcoxon rank-sum tests or
Student’s t-tests for continuous variables. Agreement
between self-reported smoking and adjusted cotinine
categories were assessed with Fleiss’ kappa statistic [39].
To characterize smoking populations, multivariable
regressions were performed to assess the relationship
between self-reported smoking status at baseline and
health outcomes over follow-up. Continuous variables
were analyzed with generalized linear mixed effects lon-
gitudinal models for change in means while logistic ran-
dom effects models were used for binary variables. For
all outcomes, the relevant chronic disease diagnosis,
symptom, or biomarker was modeled as the dependent
variable with smoking status as the independent pre-
dictor. To isolate the effects of smoking status, models
included age, sex, site, and wealth index as covariates.
Only those with complete follow-up were included in
analyses. All analyses were conducted in STATA version
13 (StataCorp, College Station, Texas, USA).
Results
Participant characteristics
A total of 404 agreed to participate in the subsample, of
which 50.2% were male with a mean age of 54.9 years old.
Twenty-two were excluded from analysis for missing urine
cotinine values. Overall, there were 2978 adult participants
in the CRONICAS cohort with complete baseline data for
analysis and 382 in a baseline subset of participants with
urine cotinine values. Neither sex nor age differed between
sites, though smoking did (Table 1). The cotinine sub-
sample did not significantly vary from the balance of the
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parent sample (Lima and Tumbes) in any measure (Add-
itional file 1: Table S1).
A total of 2583 participants (86.7%) remained in the
study through 40-month follow up. The balance of 395
(13.3%) was lost to follow up, twenty-three of whom
were deceased. Most notably, participants from urban
and rural Puno were more likely to be lost to follow up
than those from Lima or Tumbes (Additional file 1:
Table S2).
Among our full cohort at baseline, prevalence of current
smoking was about 16.5% for those aged 35–54 years.
This fell to 10% among those aged 55–64 years and 5.5%
for those aged ≥65 years (Additional file 1: Table S3). Men
were three to seven times more likely to be current or
daily smokers than women, with variations by age and site.
Daily smokers comprised 99 of the 364 self-reported
current smokers (27.2%). Occasional smokers consumed a
mean of 0.8 cigarettes per day while daily smokers con-
sumed a mean of 4.3 cigarettes per day. Among occasional
smokers, men consumed more cigarettes, but among daily
smokers, males and females consumed the same. The
highest mean number of cigarettes smoked per day by all
current smokers was in Tumbes (2.2), followed by urban
Puno (1.8), Lima (1.7), and rural Puno (0.2).
Cotinine and self-reported smoking
Sixty-one percent of participants had biological samples
obtained within one month of survey administration.
Twenty-six of our 382 sub-sample participants (6.8%) had
a urine cotinine level above zero. Among these, the
median cotinine-creatinine ratio was 207.8 mcg/mg (IQR
119.4–496.1). Median adjusted cotinine was 0.0 mcg/mg
(IQR 0–0) for both self-reported non-smokers and occa-
sional smokers in our sample, compared to 172.3 mcg/mg
(IQR 0–709.2) for daily smokers. Mean adjusted cotinine
was 6.0, 26.0, and 354.4 mcg/mg, for each group, respect-
ively (Fig. 1). The difference in mean adjusted cotinine
levels between occasional and non-smoking groups was
not significant (p = 0.79), while cotinine levels in daily
smokers were higher than in both occasional smokers and
non-smokers (p < 0.001, respectively). In our sub-sample,
high adjusted cotinine validated daily smoking (−0.8% dif-
ference, p = 0.62; Table 2). The sensitivity, specificity, posi-
tive predictive value, and negative predictive value of self-
reported daily smoking as compared to the gold standard
of high cotinine in our sample were: 61.9%, 98.6%, 72.2%,
and 97.8%, respectively. The length of time between inter-
view and urine sample did not affect the validity of self-
reported daily smoking (Additional file 1: Table S4). The
kappa statistic for agreement in classification between the
three levels of self-report and the three levels of urine co-
tinine was 0.40 (95% CI 0.31, 0.45), indicating moderate
agreement. Kappa for self-reported daily smokers and cre-
atinine- adjusted cotinine (as dichotomous categories) was
0.65 (95% CI 0.47, 0.83), indicating substantial agreement.
Characterization of smokers
Prevalence of reported symptoms, disease diagnoses,
group means of continuous biomarkers, and lung test-
ing scores by reported smoking classification for
Table 1 Demographic characteristics of recruitment sites and p-value for difference between sites, CRONICAS Study, Peru, 2010
Lima Tumbes Urban Puno Rural Puno p-value
n (%) 1004 (33.7) 966 (32.4) 503 (16.9) 506 (17.0)
Age, median (IQR) 54.7 (45.4–64.1) 54.7 (44.7–64.6) 54.8 (44.9–64.4) 54.8 (45.1–63.9) 0.82
Male, n (%) 492 (49.0) 483 (50.0) 249 (49.5) 239 (47.4) 0.82
Daily use of biomass fuels, n (%) 60 (6.0) 221 (23.4) 25 (4.8) 483 (96.6) <0.001
Education in years, n (%) <0.001
Primary or Less 424 (42.2) 524 (54.3) 72 (14.3) 318 (62.9)
Secondary 403 (40.1) 296 (30.7) 139 (27.6) 158 (31.2)
Higher than Secondary 177 (17.6) 145 (15.0) 292 (58.1) 30 (5.9)
Wealth Index, n (%) <0.001
Low 121 (12.1) 311 (32.3) 120 (23.9) 356 (70.4)
Medium 366 (36.5) 393 (40.9) 129 (25.7) 136 (26.9)
High 517 (51.5) 258 (26.8) 254 (50.5) 14 (2.8)
Smoking, n (%) <0.001
Non-smoking 855 (85.2) 843 (87.4) 447 (88.9) 469 (92.7)
Occasional 116 (11.6) 68 (7.1) 45 (9.0) 6 (7.1)
Daily 33 (3.3) 54 (5.6) 11 (2.2) 1 (0.2)
Pack-years (ever smokers), median (IQR) 0.1 (0.0–0.8) 0.5 (0.1–4.6) 0.1 (0.0–1.2) 0.1 (0.0–0.3) <0.001
Bold indicates significance at p = 0.05. Differences estimated by t-tests, Wilcoxon rank-sum, or Chi-squared tests
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baseline and 40-month follow up can be found in
Table 3 and Additional file 1: Table S5. The reported
odds ratios and differences in mean represent the oc-
casional and daily smoking groups relative to non-
smokers. Additionally, self-reported occasional
smokers in our sample had a mean lifetime smoking
history of 1.27 pack-years compared to 1.12 pack-
years among non-smokers (37% of whom were past
smokers at study baseline) (p = 0.68). Self-reported
daily smokers had a mean smoking history of 7.45
pack-years (p < 0.001 vs. occasional and non-
smokers), which was comparable to the 9.50 pack
years’ history reported by past regular smokers
(p = 0.26).
We modeled the change in lung function between
baseline and follow up. Controlling for age, sex, site, and
wealth index, daily smokers trended toward having a
greater decline in FVC (−1%; 95% CI -2.9, 0.8) and FEV1
(−1.3%; 95% CI -3.2, 0.6) over 40 months when com-
pared to non-smokers, whereas the decline in lung func-
tion was similar between occasional smokers and non-
smokers (−0.2% FVC; 95% CI -1.5, 1.0) and (0% FEV1;
95% CI -1.3, 1.3).
Daily smokers trended toward an increase in BMI
(+1.10%; 95% CI -0.09, 2.29) compared to occasional
smokers (+0.18%; 95% CI -0.61, 0.97) against non-smokers.
Occasional smokers experienced an adjusted IRR for dia-
betes of 0.94 over follow up compared to non-smokers
(95% CI 0.48, 1.84) while the IRR for daily smokers was
1.46 (95% CI 0.63, 3.37). The IRR for hypertension for occa-
sional smokers was 0.99 (95% CI 0.62, 1.56) and 0.73 (95%
CI 0.34, 1.57) for daily smokers.
Discussion
Systematic surveillance of tobacco use is an essential
step in the formation of programs to reduce smoking-
related mortality, especially for those who joined the
WHO’s Framework Convention on Tobacco Control,
which obliges signatory nations, including Peru, to
implement policy changes to reduce tobacco use [26].
In our primary analysis, based on urine cotinine, we
validate a lower prevalence of smoking in low-income
Fig. 1. Comparison of urine cotinine and adjusted cotinine values between smoking classifications: non-, occasional, current, and daily smokers.
Table 2 Comparison of smoking prevalence (%; 95% confidence interval) by ascertainment method and site, CRONICAS Study, Peru, 2010
Occasional smoking Lima
(n=195)
Tumbes
(n=187)
Total
(n=382)
Self-Report 10.3 (6.0, 14.5) 7.5 (3.7, 11.3) 8.9 (6.1, 11.8)
Creatinine-Adjusted Cotinine (10–100 mcg/mg) 0.5 (−0.5, 1.5) 2.1 (0.1, 4.2) 1.3 (0.2, 2.4)
Difference by method 9.7 (5.4, 14.1) 5.3 (1.0, 9.7) 7.6 (4.5, 10.7)
Daily smoking Lima
(n=195)
Tumbes
(n=187)
Total
(n=382)
Self-Report 3.1 (0.7, 5.5) 6.4 (2.9, 9.9) 4.7 (2.6, 6.8)
Creatinine-Adjusted Cotinine (≥100 mcg/mg) 2.1 (0.1, 4.0) 9.1 (5.0, 13.2) 5.5 (3.2, 7.8)
Difference by method 1.0 (−2.1, 4.2) −2.7 (−8.1, 2.7) −0.8 (−3.9, 2.3)
Bold indicates significance at p = 0.05. Differences estimated by t-tests
Morgan et al. Tobacco Induced Diseases  (2017) 15:32 Page 5 of 10
Table 3 Prevalence and means of chronic disease indicators at baseline and 40 month follow up, CRONICAS Study, multiple sites in
Peru, 2010
Outcome (Prevalence) N Smoking Category Baseline Second Follow-Up Adj. Odds Ratioa p-value
Hypertension, % 2583 Non-Smoking 27.2 32.2 — —
Occasional 19.3 24.0 0.86 0.75
Daily 31.9 29.7 1.46 0.60
Diabetes, % 2581 Non-Smoking 5.4 7.8 — —
Occasional 3.9 6.0 0.82 0.78
Daily 3.3 8.8 1.31 0.73
Stroke, % 2583 Non-Smoking 0.4 0.5 — —
Occasional 0.4 0.4 1.76 0.78
Daily 1.1 1.1 5.62 0.44
Cardiovascular Disease, % 2583 Non-Smoking 5.0 7.3 — —
Occasional 4.3 5.2 1.44 0.58
Daily 8.8 13.2 10.24 0.001
Overweight, % 2541 Non-Smoking 73.6 75.0 — —
Occasional 74.6 77.6 1.08 0.90
Daily 64.8 71.4 0.23 0.09
Obese, % 2541 Non-Smoking 29.3 30.1 — —
Occasional 24.1 25.9 0.30 0.14
Daily 20.9 24.2 0.09 0.035
Outcome (Mean) N Smoking Category Baseline Second Follow-Up Adj. Difference in Meana p-value
Systolic Blood Pressure (mmHg) 2543 Non-Smoking 116.8 119.2 — —
Occasional 118.2 120.1 2.02 0.06
Daily 121.2 123.2 0.98 0.54
Body Mass Index (kg/m2) 2541 Non-Smoking 27.9 28.1 — —
Occasional 27.5 27.9 −0.06 0.86
Daily 27.0 27.5 −0.74 0.11
HDL (mg/dL) 2411 Non-Smoking 41.2 45.7 — —
Occasional 41.3 44.5 1.95 0.013
Daily 40.6 43.6 0.83 0.49
LDL (mg/dL) 2410 Non-Smoking 127.7 120.9 — —
Occasional 125.2 116.5 −1.24 0.58
Daily 125.8 118.7 −1.46 0.67
Total Cholesterol (mg/dL) 2411 Non-Smoking 201.4 198.4 — —
Occasional 198.4 192.5 −0.92 0.73
Daily 196.2 194.4 −2.88 0.47
Triglycerides (mg/dL) 2411 Non-Smoking 163.2 159.0 — —
Occasional 159.5 157.5 −9.22 0.15
Daily 148.9 160.5 −12.52 0.19
HOMA-IR 2410 Non-Smoking 4.6 5.4 — —
Occasional 5.3 5.4 0.86 0.007
Daily 4.2 5.3 −0.15 0.75
Framingham Score 2376 Non-Smoking 10.8 11.4 — —
Occasional 12.8 11.1 3.26 <0.001
Daily 13.6 13.5 3.57 <0.001
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peri-urban areas than was reported in urban areas in
previous large studies. It appears that Peru is part of
a pattern seen in other Latin American countries,
with the exception of the Southern Cone, that is
characterized by smoking practices favoring occasional
over daily smoking and fewer cigarettes consumed.
The prevalence of self-reported smoking in our entire
sample (n = 2978) was 3.3% daily, 8.9% occasional,
and 12.2% current smokers. These findings are com-
patible with GATS data from Mexico [40], Costa Rica
[41], and Panama [42]: all of which feature low smok-
ing prevalence and daily smoking equal to or less
than half of current smoking. This pattern of reduced
tobacco use was previously noted by Tapia-Conyer et
al., who found that daily smoking in Mexico de-
creased from 64% to 52% between 1988 and 1998
while among daily smokers, those who smoked five or
fewer cigarettes/day increased from 49% to 74% [43].
Earlier, Samet et al. found that Hispanics in New
Mexico tended to consume about half as many ciga-
rettes as Whites, though prevalence of smoking and
years smoked were similar [44]. This pattern contrasts
with the Southern Cone countries, which have dem-
onstrated higher smoking prevalence and frequency.
Both the PLATINO and CARMELA studies report
current smoking prevalence of nearly 40% in Chile
and Argentina (WHO reports a drop to 29% in
Argentina) while figures from GATS show a lower
current smoking prevalence of 25% for Uruguay but
notes that 80% of current smokers are also daily
smokers [3, 45–47]. Menezes et al. note that only 2
of 1626 (0.12%) current smokers in the PLATINO
study were not daily smokers, contrasting remarkably
with our findings in Peru [45].
Our self-reported smoking prevalence mirrors that
published by Weygandt et al. but was substantially
less than what the CARMELA study reported from
Lima [3, 5]. In one comparison, we found 15.5%
prevalence of current smoking in peri-urban Lima
while CARMELA reported 26.6% prevalence for the
45–65 year age range [3]. For all ages in Lima, we
found a current smoking prevalence of 14.8% and for
all sites, 12.2%. Additionally, CARMELA reported
finding a mean of around 7 cigarettes consumed daily
among currently smoking men and around 5 for
women [3]. Our study found a mean of 1.8 cigarettes
per day for men and 1.1 for women among current
smokers in peri-urban Lima. However, it is important
to note that these sets of estimates are not directly
comparable: generally, CARMELA reported use of all
inhaled tobacco in an urban sample of age 25–
65 years while we report cigarette use in adults aged
≥35 years living in resource-poor settings [3]. One
should also note that the relationship between nico-
tine intake and cigarettes smoked is not completely
linear. Blackford et al. report that, in an international
sample, participants tended to titrate smoking to their
preferred nicotine level and not number of cigarettes
smoked. Subsequently, those who smoked fewer than
20 cigarettes per day (99.5% of our sample) consumed
more nicotine per cigarette than those who smoked
more [11].
In our secondary analysis, we attempted to characterize
the smoking populations of low-income areas using longi-
tudinal data. It is difficult to come to any conclusions
about the long-term risk of chronic disease between
groups, perhaps because the use of tobacco is so low, even
among daily smokers. Only 3% of our entire cohort re-
ported a history of ten or more pack-years. Considering
the general guidelines for lung cancer screening (loosely,
≥55 years old and ≥30 pack-years smoking), only 0.75% of
our sample qualified [48–51]. Furthermore, there was no
difference between mean pack-years for the occasional
and non-smoking groups, indicating that the occasionally
smoking group had a similar history to the then
non-smokers.
Considering this, the relationships between lung func-
tion, obesity, and smoking status are of note. Unadjusted
means show a greater loss of functional volume (FVC)
and ability to exhale (FEV1) for daily smokers compared
to occasional and non-smokers and the gap was made
more apparent by linear regression with age, sex, site, and
Table 3 Prevalence and means of chronic disease indicators at baseline and 40 month follow up, CRONICAS Study, multiple sites in
Peru, 2010 (Continued)
Post-Bronchodilator Forced
Vital Capacity (L)
2278 Non-Smoking 3.42 3.33 — —
Occasional 4.18 4.08 0.05 0.17
Daily 3.82 3.77 −0.07 0.21
Post-Bronchodilator Forced Expiratory
Volume in One Second (L)
2278 Non-Smoking 2.74 2.66 — —
Occasional 3.33 3.24 0.02 0.47
Daily 3.10 2.99 −0.03 0.53
Bold indicates significant results. aAdjusted for age, sex, field site, and wealth index
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wealth index, although the difference was not statistically
significant. The same pattern was found when observing
changes in BMI, with daily smokers experiencing a greater
percentage rise in BMI than occasional or non-smokers.
That pattern was also exacerbated in linear modeling
though, again, it was not significant. No association was
found with smoking status and change in systolic or dia-
stolic blood pressures. This indicates that, even with rela-
tively low levels of smoking, daily smokers in this sample
may have a worsening risk profile for chronic disease than
occasional or non-smokers. However, taking into account
the rest of our data, the groups may not be different in a
clinical way, which presents opportunities for the Peruvian
government to intervene and prevent the public health
situation from getting worse.
As an observation, multi-center surveys of smoking
prevalence such as PLATINO did not distinguish be-
tween current and daily smoking, while those using
the GATS protocol, such as CARMELA and our
group, did [3, 5, 45]. Under the usual definition of
current smoking – a small lifetime history and any
reported smoking within a month or more – no value
is given to the frequency of cigarette smoking, which,
as shown by our sample, may be very low. The
definition of active smoking from the PLATINO study
would have included all of our self-reported daily
smokers and 82% of our low-use occasional smokers,
inappropriately characterizing our sample. As
Weygandt et al. argue, including those who smoke as
infrequently as they do in our sample represents an
over-estimation of the actual active smoking preva-
lence in a population [5].
Strengths of this study include high-quality data
collection methods and surveillance of disease out-
comes, nested within a well-designed population-
based study, and standardized laboratory methods for
measuring biomarkers. Limitations of this study
include the small sample of daily smokers, which
limited statistical power in attempts to characterize
the group, and the larger number of participants lost
to follow up in the Puno field sites, which may have
skewed our health outcomes results. Additionally, the
varying time between interview and biological sample
question could change our associations but, since
people in our sample rarely changed smoking status
(our main exposure), we don’t anticipate that the lags
had any noticeable effect.
Conclusions
In summary, we used creatinine-adjusted urine cotinine to
validate observed low prevalence of self-reported active
smokers and low overall frequency of smoking in low-
income areas of Lima and Tumbes, Peru. This places Peru
within an emerging pattern of low prevalence and
frequency of smoking, favoring occasional smoking, seen
in other Latin American countries except for those in the
Southern Cone. As Peru is party to WHO’s FCTC as of
2004, it is imperative that national policymakers have
access to accurate epidemiological data on tobacco smok-
ing in order to properly implement the MPOWER
program.
In investigating longitudinal health outcomes data, we
did not observe significant differences between groups
of self-reported smokers, perhaps due to low levels of
smoking across the population. However, even with low
cigarette consumption, patterns can be seen that favor
worsening lung function and BMI over time for daily
smokers compared to occasional and non-smokers.
As a final observation, we recommend the use of the
Global Adult Tobacco Survey protocol – which distin-
guishes between daily and current smoking – for tobacco
use surveillance in future epidemiological studies. This
would be especially useful in characterizing regions such
as Peru, where the sole use of current smoking as an indi-
cator overestimates the real prevalence of active smoking.
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